BLMH.c recent earnings exaggerate its undervaluation. Bloom Health Partners (CSE: BLMH) has reported another successful quarter, bringing its year-to-date revenues to C$24.9 million. This puts the company well on track to smash yearly guidance of C$25M – C$28M,
These earnings mark an even greater disparity in the company’s current valuation of C$8.5 million. For a healthcare technology company, BLMH’s current P/S ratio of .35 is drastically unbalanced. The current average across the market is 4.05, meaning BLMH should theoretically be valued at around C$100.845M.
In my opinion, it is only a matter of time before the community at large catches onto this extreme undervaluation. Once BLMH reports its yearly earnings and smashes its most bullish guidance, it’s going to be GG.
BLMH.c is currently trading at $.185.
https://ceo.ca/@newsfile/bloom-health-partners-reports-profitable-fiscal-q3